Remission and recovery associated with lurasidone in the treatment of major depressive disorder with subthreshold hypomanic symptoms (mixed features): post-hoc analysis of a randomized, placebo-controlled study with longer-term extension—CORRIGENDUM

doi: 10.1017/S1092852917000025. Published by Cambridge University Press, 7 March 2017.

Incorrect disclosure verbiage resulting from an interactive online submission form was discovered in Goldberg et al 2017. Thanks to Dr. Joseph F. Goldberg for discovering the error. The error relates to the wording of the disclosure in the original article, which incorrectly suggests that the authors received “personal fees” from Sunovion and from other companies, instead of research grants, speaker fees, and consulting fees.

The corrected disclosure statement can be found here. The error is the complete responsibility of the coauthors.

Disclosures

Dr. Goldberg has received consulting fees from, and served on the speakers’ bureau for, Sunovion Pharmaceuticals Inc. He has served on the speakers’ bureau for Merck, Takeda-Lundbeck, and Vanda Pharmaceuticals, has received consulting fees from WebMD and Medscape, and royalties from American Psychiatric Publishing, Inc.

Dr. Siu has received funding and consulting fees from Sunovion that support research and the use of lurasidone clinical trial databases for analyses to support the preparation of this manuscript. She has also received funding and consulting fees from Schizophrenia Program, Centre for Addiction and Mental Health, University of Toronto, Pfizer, Hong Kong Health and Medical Research Grant, and the Chinese University of Hong Kong that support research and the use of clinical trial and genetic databases for analyses, preparation of manuscripts, and data science activities.

Drs. Ng-Mak, Rajagopalan, and Loebel are employees of Sunovion Pharmaceuticals Inc. Dr. Chuang was an employee of Sunovion Pharmaceuticals Inc. during the development and drafting of the manuscript. She is now at Vertex Pharmaceuticals.